New Horizons in The Management of Acute Myeloid Leukemia (AML): How Novel Therapies Are Changing the Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from April 1, 2019 to April 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie, Astellas, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals

Description:
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. AML has several subtypes and treatment and prognosis vary among subtypes. After AML has been diagnosed, tests are done to find out the subtype which is especially important, as several new treatments focus on AML disease with certain mutations, including IDH2. Following older treatment paradigms, AML has been cured in 35–40% of people under 60 years old, but only in 5–15% of people over 60 years old. Fortunately for people with AML, that treatment paradigm has begun to change drastically, as novel targeted agents have shown improved efficacy and safety outcomes in clinical trial research. The emerging predictive and prognostic factors, identification of patients who will benefit from these novel therapies, and recent clinical research on new targeted agents, novel cytotoxic agents, and epigenetic modifiers will ultimately optimize the treatment of patients with AML.

Upon completion of this activity, participants will be able to:

  • Summarize efficacy and safety evidence on novel therapeutics in acute myeloid leukemia (AML), including newer targeted, cytotoxic, and antibody-based strategies, in a range of patient populations

  • Analyze the role of cytotoxic therapy options in the evolving treatment paradigm in AML

  • Examine baseline factors, including age, functional status, antecedent hematologic disorders, therapy-related disease, cytogenetic and mutational findings, among others, that may influence treatment decisions in AML

  • Explore strategies to manage treatment-related adverse events in patients with AML on therapy with regimens containing novel components

  • Discuss the managed care considerations of novel therapies by exploring where these agents fit into current AML management paradigm

  • Assess available clinical data on novel agents and combination regimens in high-risk AML
     

Faculty: Timothy Kubal, MD, MBA
Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center

Jeffrey Lancet, MD
Senior Member & Professor
Chair, Department of Malignant Hematology
Moffitt Cancer Center

Disclosure:

Dr. Kubal has no relevant financial relationships to disclose.

Dr. Lancet serves on an advisory board for Jazz Pharmaceuticals. He serves as a consultant for AbbVie, Astellas, Celgene, Daiichi Sankyo, and Pfizer. He has previously received grant support from Pfizer, however that relationship has been terminated. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie, Astellas, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue